# US 2026/0092933 A1 · Apparatus for measuring glycation of red blood cells and glycated hemoglobin level using physical and electrical characteristics of cells, and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092933 A1
- Document ID: US20260092933A1
- Status: Published application
- Kind: A1
- Application number: 19/287,299
- Filed: 2025-07-31
- Published: 2026-04-02
- Earliest claimed: 2021-09-29
- Assignees: Orange Biomed Ltd., Co.
- Applicants: Orange Biomed Co., Ltd.
- Inventors: Ung Hyeon Ko; Seung Jin Kang; Eun Young Park
- Web page: https://patentgrep.com/patent/US20260092933A1

## CPC

- G01N 33/726: {Devices}
- B01L 3/00: Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L 3/502715: {characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces}
- G01N 27/02: by investigating impedance
- G01N 27/327: Biochemical electrodes {, e.g. electrical or mechanical details for in vitro measurements}
- G01N 33/49: Blood {(chemical methods for determining blood cell populations G01N33/5094; chemical analysis of blood groups or blood types G01N33/80)}
- G01N 33/72: involving blood pigments, e.g. haemoglobin, bilirubin {or other porphyrins; involving occult blood}
- G01N 33/723: {Glycosylated haemoglobin}
- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- B01L 2200/027: for microfluidic devices
- B01L 2200/10: Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
- B01L 2200/14: Process control and prevention of errors
- B01L 2300/0645: Electrodes
- B01L 2300/0816: Cards, e.g. flat sample carriers usually with flow in two horizontal directions
- B01L 2300/087: Multiple sequential chambers
- B01L 2400/0403: specific forces
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE

## Abstract

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A sample testing apparatus, comprising:
a substrate having an inlet configured to receive a blood sample with red blood cells suspended therein, an outlet configured to release the blood sample, and a microchannel extending therebetween, wherein the microchannel is sized to compress individual ones of the red blood cells traveling therein;
first and second electrodes on or embedded in the substrate, wherein the first and second electrodes are spaced apart along the microchannel to define a first detection region therebetween; and
third and fourth electrodes on or embedded in the substrate, wherein the third and fourth electrodes are spaced apart along the microchannel to define a second detection region therebetween, wherein the second detection region is positioned between the first detection region and the outlet.

### Claim 12 (depends on 11)

The sample testing apparatus of claim 11, wherein each of the first, second, third, and fourth electrodes extends generally perpendicular to the microchannel.

### Claim 13 (depends on 11)

The sample testing apparatus of claim 11, further comprising:
a fifth electrode positioned between the first and second electrodes; and
a sixth electrode positioned between the third and fourth electrodes.

### Claim 14 (depends on 11)

The sample testing apparatus of claim 11, wherein each of the first, second, third, and fourth electrodes has a length between 5 micrometers and 25 micrometers.

### Claim 15 (depends on 11)

The sample testing apparatus of claim 11, wherein each of the first, second, third, and fourth electrodes has a first width adjacent the microchannel and a second width farther from the microchannel, wherein, the second width is greater than the first width.

### Claim 16 (depends on 11)

The sample testing apparatus of claim 11, wherein each of the first, second, third, and fourth electrodes is positioned to directly contact individual ones of the red blood cells traveling in the microchannel.

### Claim 17 (depends on 11)

The sample testing apparatus of claim 11, wherein the inlet has a first width and the outlet has a second width less than the first width.

### Claim 18 (depends on 11)

The sample testing apparatus of claim 11, wherein the inlet has a first depth and the outlet has a second depth less than the first depth.

### Claim 19 (depends on 11)

The sample testing apparatus of claim 11, wherein the microchannel and the first, second, third, and fourth electrodes are configured for detecting abnormal impedance signals indicating abnormal cells.

### Claim 20 (depends on 11)

The sample testing apparatus of claim 11, wherein the microchannel has a width between 4 micrometers and 10 micrometers for compressing the red blood cells traveling in the microchannel.

### Claim 21

A sample testing system, comprising:
a substrate having a cell-deforming microchannel configured to deform blood cells in a fluid sample from a user while the fluid sample travels along the cell-deforming microchannel via capillary action;
a detection circuit configured to detect a deformation-related parameter of individual ones of the blood cells being deformed by the cell-deforming microchannel; and
a controller in communication with the detection circuit and programmed to determine an analyte level of the user based on the measured deformation-related parameter.

### Claim 22 (depends on 21)

The sample testing system of claim 21, wherein the detection circuit is configured to detect the deformation-related parameter by:
outputting energy along a zone in which each of the deformed blood cells moves, and
detecting one or more deformation-related effects to the energy indicative of the deformation-related parameter.

### Claim 23 (depends on 21)

The sample testing system of claim 21, wherein the substrate further includes electrodes positioned on opposite sides of the cell-deforming microchannel, and wherein the detection circuit includes an impedance sensor coupled to the electrodes of the substrate.

### Claim 24 (depends on 21)

The sample testing system of claim 21, wherein the deformation-related parameter is a speed of the individual ones of the blood cells.

### Claim 25 (depends on 21)

The sample testing system of claim 21, wherein the deformation-related parameter is a residence time of the individual ones of the blood cells in the cell-deforming microchannel.

### Claim 26 (depends on 21)

The sample testing system of claim 21, wherein the deformation-related parameter is associated with a stiffness or a rigidity of the individual ones of the blood cells, and wherein the analyte level is correlated with the stiffness or the rigidity of the individual ones of the blood cells.

### Claim 27 (depends on 21)

The sample testing system of claim 21, wherein the controller is programmed to determine the analyte level of the user based on a distribution of the measured deformation-related parameter of the individual ones of the blood cells.

### Claim 28 (depends on 21)

The sample testing system of claim 21, wherein the controller is programmed to determine the analyte level of the user based on a uniformity level of the measured deformation-related parameter of the individual ones of the blood cells.

### Claim 29 (depends on 21)

The sample testing system of claim 21, wherein the analyte level is a glycated hemoglobin level of the user.

### Claim 30 (depends on 21)

The sample testing system of claim 21, wherein the analyte level is a management status of the user's glycated hemoglobin level.
